Sp1/3/4 Cancer Research Results

Sp1/3/4, Specificity Protein: Click to Expand ⟱
Source:
Type:
SP2 (Specificity Protein 2) and SP3 (Specificity Protein 3) are also members of the Sp/KLF (Sp1/Krüppel-like factor) family of transcription factors, similar to SP1. They share some functional similarities but also have distinct roles in cellular processes and cancer biology.
-Sp proteins are a family of transcription factors that play a crucial role in regulating gene expression.
-SP1 is often overexpressed in various types of cancer, including breast, prostate, and lung cancers. However, expression levels of Sp in normal cells and tissues are low to undetectable.

SP inhibitors:
-Curcumin, Resveratrol, EGCG, Genistein, Piperlongumine, Betulinic acid
Scientific Papers found: Click to Expand⟱
3174- Ash,    Withaferin A Acts as a Novel Regulator of Liver X Receptor-α in HCC
- in-vitro, HCC, HepG2 - in-vitro, HCC, Hep3B - in-vitro, HCC, HUH7
NF-kB↓, angioG↓, Inflam↓, TumCP↓, TumCMig↓, TumCI↓, Sp1/3/4↓, VEGF↓, angioG↓, uPA↓, PDGF↓, MCP1↓, ICAM-1↓, *NRF2↑, *hepatoP↑,
1358- Ash,    Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms
- Review, Var, NA
TumCCA↑, Apoptosis↑, TumAuto↑, Ferroptosis↑, TumCP↓, CSCs↓, TumMeta↓, EMT↓, angioG↓, Vim↓, HSP90↓, annexin II↓, m-FAM72A↓, BCR-ABL↓, Mortalin↓, NRF2↓, cMYB↓, ROS↑, ChemoSen↑, eff↑, ChemoSen↑, ChemoSen↑, eff↑, *BioAv↓, ROCK1↓, TumCI↓, Sp1/3/4↓, VEGF↓, Hif1a↓, EGFR↓,
1178- Ash,    Withaferin A suppresses the expression of vascular endothelial growth factor in Ehrlich ascites tumor cells via Sp1 transcription factor
- in-vitro, Nor, HUVECs - in-vivo, NA, NA
*VEGF↓, *angioG↓, *ascitic↓, *Sp1/3/4↓,
2702- BBR,    The enhancement of combination of berberine and metformin in inhibition of DNMT1 gene expression through interplay of SP1 and PDPK1
- in-vitro, Lung, A549 - in-vitro, Lung, H1975
TumCG↓, MAPK↓, FOXO3↑, TumCCA↑, TumCMig↓, TumCI↓, Sp1/3/4↓, PDK1↓, DNMT1↓, eff↑,
5593- BetA,    Betulinic acid decreases specificity protein 1 (Sp1) level via increasing the sumoylation of sp1 to inhibit lung cancer growth
- in-vitro, Lung, NA
Sp1/3/4↓, cycA1/CCNA1↓, p‑RB1↓, TumCCA↑,
5591- BetA,    Advances and challenges in betulinic acid therapeutics and delivery systems for breast cancer prevention and treatment
- Review, BC, NA
BioAv↓, BioAv↑, selectivity↑, eff↑, angioG↓, *antiOx↑, *Inflam↓, MMP↓, Bcl-2↓, BAX↑, Casp9↑, Casp3↑, GRP78/BiP?, ER Stress↑, PERK↑, CHOP↑, ChemoSen↑, SESN2↑, ROS↑, MOMP↓, MAPK↑, Cyt‑c↑, AIF↑, STAT3↓, FAK↓, TIMP2↑, TumCMig↓, TumCI↓, Sp1/3/4↓, TumCCA↑, DNAdam↑,
2727- BetA,    Betulinic acid in the treatment of breast cancer: Application and mechanism progress
- Review, BC, NA
mt-ROS↑, Sp1/3/4↓, TumMeta↓, GlucoseCon↓, NF-kB↓, ChemoSen↑, chemoP↑, m-Apoptosis↑, TOP1↓,
2729- BetA,    Betulinic acid in the treatment of tumour diseases: Application and research progress
- Review, Var, NA
ChemoSen↑, mt-ROS↑, STAT3↓, NF-kB↓, selectivity↑, *toxicity↓, eff↑, GRP78/BiP↑, MMP2↓, P90RSK↓, TumCI↓, EMT↓, MALAT1↓, Glycolysis↓, AMPK↑, Sp1/3/4↓, Hif1a↓, angioG↓, NF-kB↑, NF-kB↓, MMP↓, Cyt‑c↑, Casp9↑, Casp3↑, RadioS↑, PERK↑, CHOP↑, *toxicity↓,
2731- BetA,    Betulinic Acid for Glioblastoma Treatment: Reality, Challenges and Perspectives
- Review, GBM, NA - Review, Park, NA - Review, AD, NA
BBB↑, *GSH↑, *Catalase↑, *motorD↑, *neuroP↑, *cognitive↑, *ROS↓, *antiOx↑, *Inflam↓, MMP↓, STAT3↓, NF-kB↓, Sp1/3/4↓, TOP1↓, EMT↓, Hif1a↓, VEGF↓, ChemoSen↑, RadioS↑, BioAv↓,
2735- BetA,    Betulinic acid as apoptosis activator: Molecular mechanisms, mathematical modeling and chemical modifications
- Review, Var, NA
mt-Apoptosis↑, Casp↑, p38↑, MAPK↓, JNK↓, VEGF↓, AIF↑, Cyt‑c↑, ROS↑, Ca+2↑, ATP↓, NF-kB↓, ATF3↓, TOP1↓, VEGF↓, survivin↓, Sp1/3/4↓, MMP↓, ChemoSen↑, selectivity↑, BioAv↓, BioAv↑, BioAv↑, BioAv↑, BioAv↑,
2736- BetA,  Chemo,    Multifunctional Roles of Betulinic Acid in Cancer Chemoprevention: Spotlight on JAK/STAT, VEGF, EGF/EGFR, TRAIL/TRAIL-R, AKT/mTOR and Non-Coding RNAs in the Inhibition of Carcinogenesis and Metastasis
- Review, Var, NA
chemoPv↑, p‑STAT3↓, JAK1↓, JAK2↓, VEGF↓, EGFR↓, Cyt‑c↑, Diablo↑, AMPK↑, mTOR↓, Sp1/3/4↓, DNAdam↑, Gli1↓, GLI2↓, PTCH1↓, MMP2↓, MMP9↓, miR-21↓, SOD2↓, ROS↑, Apoptosis↑,
2738- BetA,    Betulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vivo, NA, NA
TumCI↓, TumCMig↓, Glycolysis↓, lactateProd↓, GRP78/BiP↑, ER Stress↑, PERK↑, p‑eIF2α↑, β-catenin/ZEB1↓, cMyc↓, ROS↑, angioG↓, Sp1/3/4↓, DNAdam↑, TOP1↓, TumMeta↓, MMP2↓, MMP9↓, N-cadherin↓, Vim↓, E-cadherin↑, EMT↓, LDHA↓, p‑PDK1↓, PDK1↓, ECAR↓, OCR↓, Hif1a↓, STAT3↓,
2759- BetA,    Chemopreventive and Chemotherapeutic Potential of Betulin and Betulinic Acid: Mechanistic Insights From In Vitro, In Vivo and Clinical Studies
- Review, Var, NA
chemoPv↑, ChemoSen↑, *Inflam↓, *NRF2↑, *NF-kB↓, *COX2↓, ROS↑, MMP↓, Sp1/3/4↓, VEGF↓,
2737- BetA,    Multiple molecular targets in breast cancer therapy by betulinic acid
- Review, Var, NA
TumCP↓, Cyc↓, TOP1↓, TumCCA↑, angioG↓, NF-kB↓, Sp1/3/4↓, VEGF↓, MMPs↓, ChemoSen↑, eff↑, MMP↓, ROS↑, Bcl-2↓, Bcl-xL↓, Mcl-1↓, lipid-P↑, RadioS↑, eff↑,
2743- BetA,    Betulinic acid and the pharmacological effects of tumor suppression
- Review, Var, NA
ROS↑, MMP↓, Cyt‑c↑, Apoptosis↑, TumCCA↑, Sp1/3/4↓, STAT3↓, NF-kB↓, EMT↓, TOP1↓, MAPK↑, p38↑, JNK↑, Casp↑, Bcl-2↓, BAX↑, VEGF↓, LAMs↓,
2745- BetA,    Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors
- in-vitro, CRC, RKO - in-vitro, CRC, SW480 - in-vivo, NA, NA
Apoptosis↑, TumCG↓, Sp1/3/4↓, survivin↓, VEGF↓, p65↓, EGFR↓, cycD1/CCND1↓, ROS↑, MMP↓,
2754- BetA,    Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors
- in-vitro, Pca, LNCaP
VEGF↓, survivin↓, Sp1/3/4↓, Casp↑, PARP↑, survivin↓, angioG↓,
5954- CEL,    The molecular mechanisms of celecoxib in tumor development
- Review, Var, NA
TumCP↓, TumCMig↓, TumCI↓, COX2↓, p‑NF-kB↓, Akt↓, MMP2↓, MMP9↓, Apoptosis↑, mitResp↑, ER Stress↑, TumAuto↑, ChemoSen↑, Inflam↓, PGE2↓, chemoPv↑, toxicity↓, Risk↓, PI3K↓, RadioS↑, TumCMig↓, TumCI↓, cJun↓, Sp1/3/4↓, ROS↑, MMP↓, MPT↑, Ca+2↑, Glycolysis↓, ATP↓, CSCs↓, Wnt/(β-catenin)↓, EMT↓, toxicity↝,
2653- Cela,    Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence
- Review, Var, NA
chemoPv↑, Catalase↑, ROS↑, HSP90↓, Sp1/3/4↓, AMPK↑, P53↑, JNK↑, ER Stress↑, MMP↓, TumCCA↑, TumAuto↑, Hif1a↑, Akt↑, other↓, Prx↓,
2688- CUR,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, Var, NA - Review, AD, NA
*ROS↓, *SOD↑, p16↑, JAK2↓, STAT3↓, CXCL12↓, IL6↓, MMP2↓, MMP9↓, TGF-β↓, α-SMA↓, LAMs↓, DNAdam↑, *memory↑, *cognitive↑, *Inflam↓, *antiOx↑, *NO↑, *MDA↓, *ROS↓, DNMT1↓, ROS↑, Casp3↑, Apoptosis↑, miR-21↓, LC3II↓, ChemoSen↑, NF-kB↓, CSCs↓, Nanog↓, OCT4↓, SOX2↓, eff↑, Sp1/3/4↓, miR-27a-3p↓, ZBTB10↑, SOX9?, ChemoSen↑, VEGF↓, XIAP↓, Bcl-2↓, cycD1/CCND1↓, BioAv↑, Hif1a↓, EMT↓, BioAv↓, PTEN↑, VEGF↓, Akt↑, EZH2↓, NOTCH1↓, TP53↑, NQO1↑, HO-1↑,
2980- CUR,    Inhibition of NF B and Pancreatic Cancer Cell and Tumor Growth by Curcumin Is Dependent on Specificity Protein Down-regulation
- in-vivo, PC, NA
TumCG↓, p50↓, p65↓, NF-kB↓, Sp1/3/4↓, MMP↓, ROS↑,
2979- CUR,  GB,    Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death
- in-vitro, Lung, H157 - in-vitro, Lung, H1299
EGFR↓, Sp1/3/4↓, ERK↓, MEK↓, Akt↓, S6K↓,
2978- CUR,    N-acetyl cysteine mitigates curcumin-mediated telomerase inhibition through rescuing of Sp1 reduction in A549 cells
- in-vitro, Lung, A549
ROS↑, hTERT/TERT↓, Sp1/3/4↓, eff↓,
2977- CUR,    Curcumin Down-Regulates Toll-Like Receptor-2 Gene Expression and Function in Human Cystic Fibrosis Bronchial Epithelial Cells
- in-vitro, CF, NA
*TLR2↓, *Sp1/3/4↓,
2976- CUR,    Curcumin suppresses the proliferation of oral squamous cell carcinoma through a specificity protein 1/nuclear factor‑κB‑dependent pathway
- in-vitro, Oral, HSC3 - in-vitro, HNSCC, CAL33
tumCV↓, Sp1/3/4↓, p65↓, HSF1↓, NF-kB↓,
2975- CUR,    Curcumin inhibits proliferation, migration and neointimal formation of vascular smooth muscle via activating miR-22
- in-vivo, Nor, NA
*miR-22↑, *Sp1/3/4↓,
2974- CUR,    Curcumin Suppresses Metastasis via Sp-1, FAK Inhibition, and E-Cadherin Upregulation in Colorectal Cancer
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29 - in-vitro, CRC, HCT15 - in-vitro, CRC, COLO205 - in-vitro, CRC, SW-620 - in-vivo, NA, NA
TumCMig↓, TumCI↓, TumCG↓, TumMeta↓, Sp1/3/4↓, HDAC4↓, FAK↓, CD24↓, E-cadherin↑, EMT↓, TumCP↓, NF-kB↓, AP-1↝, STAT3↓, P53?, β-catenin/ZEB1↓, NOTCH1↝, Hif1a↝, PPARα↝, Rho↓, MMP2↓, MMP9↓,
643- EGCG,    New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate
- Analysis, NA, NA
H2O2↑, Fenton↑, PDGFR-BB↑, EGFR↓, VEGFR2↓, IGFR↓, Ca+2↑, NO↑, Sp1/3/4↓, NF-kB↓, AP-1↓, STAT1↓, STAT3↓, FOXO↓, mtDam↑, TumAuto↑,
2993- EGCG,    Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells
- in-vitro, Pca, LNCaP
TumCG↓, PSA↓, HK2↓, AR↓, Sp1/3/4↓,
2992- EGCG,    Effects of Epigallocatechin-3-Gallate on Matrix Metalloproteinases in Terms of Its Anticancer Activity
- Review, Var, NA
AP-1↓, Sp1/3/4↓, NF-kB↓, ERK↓, P-gp↓, HSP27↓, β-catenin/ZEB1↓, MMPs↓, TNF-α↓, IL1β↓, MMP2↓,
2997- GEN,    Genistein Inhibition of Topoisomerase IIα Expression Participated by Sp1 and Sp3 in HeLa Cell
- in-vitro, Cerv, HeLa
TOP2↓, Sp1/3/4↓, Apoptosis↑, TumCCA↑,
3262- Lyco,    Lycopene inhibits matrix metalloproteinase-9 expression and down-regulates the binding activity of nuclear factor-kappa B and stimulatory protein-1
- in-vitro, adrenal, SK-HEP-1
TumCI↓, MMP9↓, NF-kB↓, Sp1/3/4↓, IGF-1R↓, i-ROS↓,
4949- PEITC,    Phenethyl Isothiocyanate Exposure Promotes Oxidative Stress and Suppresses Sp1 Transcription Factor in Cancer Stem Cells
- in-vitro, Cerv, HeLa
ROS↑, selectivity↑, CSCs↓, Sp1/3/4↓, P-gp↓, ALDH↓, GSH↓, TumCP↓, Apoptosis↑,
2995- PL,    Piperlongumine overcomes osimertinib resistance via governing ubiquitination-modulated Sp1 turnover
- in-vitro, Lung, H1975 - in-vitro, Lung, PC9 - in-vivo, NA, NA
Sp1/3/4↓, cMET↓, Apoptosis↑, Cyt‑c↑, p‑ERK↓, p‑Akt↓, TumCG↓,
2940- PL,    Piperlongumine Induces Reactive Oxygen Species (ROS)-dependent Downregulation of Specificity Protein Transcription Factors
- in-vitro, PC, PANC1 - in-vitro, Lung, A549 - in-vitro, Kidney, 786-O - in-vitro, BC, SkBr3
ROS↑, TumCP↓, Apoptosis↑, eff↓, Sp1/3/4↓, cycD1/CCND1↓, survivin↓, cMyc↓, EGFR↓, cMET↓,
2946- PL,    Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent
- Review, Var, NA
ROS↑, GSH↓, DNAdam↑, ChemoSen↑, RadioS↑, BioEnh↑, selectivity↑, BioAv↓, eff↑, p‑Akt↓, mTOR↓, GSK‐3β↓, β-catenin/ZEB1↓, HK2↓, Glycolysis↓, Cyt‑c↑, Casp9↑, Casp3↑, Casp7↑, cl‑PARP↑, TrxR↓, ER Stress↑, ATF4↝, CHOP↑, Prx4↑, NF-kB↓, cycD1/CCND1↓, CDK4↓, CDK6↓, p‑RB1↓, RAS↓, cMyc↓, TumCCA↑, selectivity↑, STAT3↓, NRF2↑, HO-1↑, PTEN↑, P-gp↓, MDR1↓, MRP1↓, survivin↓, Twist↓, AP-1↓, Sp1/3/4↓, STAT1↓, STAT6↓, SOX4↑, XBP-1↑, P21↑, eff↑, Inflam↓, COX2↓, IL6↓, MMP9↓, TumMeta↓, TumCI↓, ICAM-1↓, CXCR4↓, VEGF↓, angioG↓, Half-Life↝, BioAv↑,
2948- PL,    The promising potential of piperlongumine as an emerging therapeutics for cancer
- Review, Var, NA
tumCV↓, TumCP↓, TumCI↓, angioG↓, EMT↓, TumMeta↓, *hepatoP↑, *lipid-P↓, *GSH↑, cardioP↑, CycB/CCNB1↓, cycD1/CCND1↓, CDK2↓, CDK1↓, CDK4↓, CDK6↓, PCNA↓, Akt↓, mTOR↓, Glycolysis↓, NF-kB↓, IKKα↓, JAK1↓, JAK2↓, STAT3↓, ERK↓, cFos↓, Slug↓, E-cadherin↑, TOP2↓, P53↑, P21↑, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, Casp8↑, p‑HER2/EBBR2↓, HO-1↑, NRF2↑, BIM↑, p‑FOXO3↓, Sp1/3/4↓, cMyc↓, EGFR↓, survivin↓, cMET↓, NQO1↑, SOD2↑, TrxR↓, MDM2↓, p‑eIF2α↑, ATF4↑, CHOP↑, MDA↑, Ki-67↓, MMP9↓, Twist↓, SOX2↓, Nanog↓, OCT4↓, N-cadherin↓, Vim↓, Snail↓, TumW↓, TumCG↓, HK2↓, RB1↓, IL6↓, IL8↓, SOD1↑, RadioS↑, ChemoSen↑, toxicity↓, Sp1/3/4↓, GSH↓, SOD↑,
923- QC,    Quercetin as an innovative therapeutic tool for cancer chemoprevention: Molecular mechanisms and implications in human health
- Review, Var, NA
ROS↑, GSH↓, Ca+2↝, MMP↓, Casp3↑, Casp8↑, Casp9↑, other↓, *ROS↓, *NRF2↑, HO-1↑, TumCCA↑, Inflam↓, STAT3↓, DR5↑, P450↓, MMPs↓, IFN-γ↓, IL6↓, COX2↓, IL8↓, iNOS↓, TNF-α↓, cl‑PARP↑, Apoptosis↑, P53↑, Sp1/3/4↓, survivin↓, TRAILR↑, Casp10↑, DFF45↑, TNFR 1↑, Fas↑, NF-kB↓, IKKα↓, cycD1/CCND1↓, Bcl-2↓, BAX↑, PI3K↓, Akt↓, E-cadherin↓, Vim↓, β-catenin/ZEB1↓, cMyc↓, EMT↓, MMP2↓, NOTCH1↓, MMP7↓, angioG↓, TSP-1↑, CSCs↓, XIAP↓, Snail↓, Slug↓, LEF1↓, P-gp↓, EGFR↓, GSK‐3β↓, mTOR↓, RAGE↓, HSP27↓, VEGF↓, TGF-β↓, COL1↓, COL3A1↓,
3079- RES,    Therapeutic role of resveratrol against hepatocellular carcinoma: A review on its molecular mechanisms of action
- Review, Var, NA
angioG↓, TumMeta↓, ChemoSen↑, NADPH↑, SIRT1↑, NF-kB↓, NLRP3↓, Dose↝, COX2↓, MMP9↓, PGE2↓, TIMP1↑, TIMP2↑, Sp1/3/4↓, p‑JNK↓, uPAR↓, ROS↓, CXCR4↓, IL6↓, Gli1↓, *ROS↓, *GSTs↑, *SOD↑, *Catalase↑, *GPx↑, *lipid-P↓, *GSH↑, eff↑, eff↑, eff↑,
2990- RES,    Resveratrol reduces cerebral edema through inhibition of de novo SUR1 expression induced after focal ischemia
- in-vivo, Stroke, NA
*OS↑, *antiOx↑, Sp1/3/4↓,
2989- RES,    Resveratrol Represses Pokemon Expression in Human Glioma Cells
- in-vitro, GBM, NA
FBI-1↓, Sp1/3/4↓,
2981- RES,    Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways
- in-vitro, Colon, HT-29 - in-vitro, Colon, SW48
TumCCA↑, p27↑, cycD1/CCND1↓, TumCP↓, IGF-1R↓, Akt↓, Wnt↓, P53↑, Apoptosis↑, Sp1/3/4↓, cl‑PARP↑, β-catenin/ZEB1↓, MDM2↓,
2982- RES,    The flavonoid resveratrol suppresses growth of human malignant pleural mesothelioma cells through direct inhibition of specificity protein 1
- in-vitro, Melanoma, MSTO-211H
tumCV↓, Apoptosis↑, Sp1/3/4↓, p27↓, P21↓, cycD1/CCND1↓, Mcl-1↓, survivin↓,
2983- RES,    Resveratrol Improves Diabetic Retinopathy via Regulating MicroRNA-29b/Specificity Protein 1/Apoptosis Pathway by Enhancing Autophagy
- in-vitro, Nor, NA
*Beclin-1↑, *p62↓, *Sp1/3/4↓, *Apoptosis↓,
2984- RES,    Involvement of miR-539-5p in the inhibition of de novo lipogenesis induced by resveratrol in white adipose tissue
- in-vivo, Nor, NA
*Sp1/3/4↓, *SREBP1↓, *FASN↓,
2985- RES,    Resveratrol Inhibits Diabetic-Induced Müller Cells Apoptosis through MicroRNA-29b/Specificity Protein 1 Pathway
- in-vivo, Nor, NA - vitro+vivo, Diabetic, NA
*Sp1/3/4↓, *miR-29b↑,
2988- RES,    The Antimetastatic Effects of Resveratrol on Hepatocellular Carcinoma through the Downregulation of a Metastasis-Associated Protease by SP-1 Modulation
- in-vitro, HCC, HUH7
TumCMig↓, TumCI↓, uPA↓, Sp1/3/4↓,
2991- RES,  Chemo,    Synergistic anti-cancer effects of resveratrol and chemotherapeutic agent clofarabine against human malignant mesothelioma MSTO-211H cells
- in-vitro, Melanoma, MSTO-211H - in-vitro, Nor, MeT5A
eff↑, selectivity↑, Sp1/3/4↓,
104- RES,  QC,    Resveratrol and Quercetin in Combination Have Anticancer Activity in Colon Cancer Cells and Repress Oncogenic microRNA-27a
- in-vitro, Colon, HT-29
Casp3↑, PARP↑, survivin↓, miR-27a-3p↓, Sp1/3/4↓, ZBTB10↑, ROS⇅, TAC↑, tumCV↓,
3192- SFN,    Transcriptome analysis reveals a dynamic and differential transcriptional response to sulforaphane in normal and prostate cancer cells and suggests a role for Sp1 in chemoprevention
- in-vitro, Pca, PC3
Sp1/3/4↓, selectivity↑, NRF2↑, HDAC↓, DNMTs↓, TumCCA↑, selectivity↑, HO-1↑, NQO1↑, CDK2↓, TumCP↓, BID↑, Smad1↑, Diablo↑, ICAD↑, Cyt‑c↑, IAP1↑, HSP27↑, *Cyt‑c↓, *IAP1↓, *HSP27↓, survivin↓, CDK4↓, VEGF↓, AR↓,

Showing Research Papers: 1 to 50 of 53
Page 1 of 2 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 53

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ATF3↓, 1,   Catalase↑, 1,   Fenton↑, 1,   Ferroptosis↑, 1,   GSH↓, 4,   H2O2↑, 1,   HO-1↑, 5,   lipid-P↑, 1,   MDA↑, 1,   NQO1↑, 3,   NRF2↓, 1,   NRF2↑, 3,   Prx↓, 1,   Prx4↑, 1,   ROS↓, 1,   ROS↑, 18,   ROS⇅, 1,   i-ROS↓, 1,   mt-ROS↑, 2,   SOD↑, 1,   SOD1↑, 1,   SOD2↓, 1,   SOD2↑, 1,   TAC↑, 1,   TrxR↓, 2,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 2,   ATP↓, 2,   BCR-ABL↓, 1,   MEK↓, 1,   mitResp↑, 1,   MMP↓, 12,   Mortalin↓, 1,   MPT↑, 1,   mtDam↑, 1,   OCR↓, 1,   XIAP↓, 2,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 3,   cMyc↓, 5,   ECAR↓, 1,   FBI-1↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 5,   HK2↓, 3,   lactateProd↓, 1,   LDHA↓, 1,   NADPH↑, 1,   PDK1↓, 2,   p‑PDK1↓, 1,   PPARα↝, 1,   S6K↓, 1,   SIRT1↑, 1,  

Cell Death ⓘ

Akt↓, 5,   Akt↑, 2,   p‑Akt↓, 2,   Apoptosis↑, 13,   m-Apoptosis↑, 1,   mt-Apoptosis↑, 1,   BAX↑, 4,   Bcl-2↓, 6,   Bcl-xL↓, 1,   BID↑, 1,   BIM↑, 1,   Casp↑, 3,   Casp10↑, 1,   Casp3↑, 7,   Casp7↑, 2,   Casp8↑, 2,   Casp9↑, 4,   Cyt‑c↑, 8,   Diablo↑, 2,   DR5↑, 1,   Fas↑, 1,   Ferroptosis↑, 1,   hTERT/TERT↓, 1,   IAP1↑, 1,   ICAD↑, 1,   iNOS↓, 1,   JNK↓, 1,   JNK↑, 2,   p‑JNK↓, 1,   MAPK↓, 2,   MAPK↑, 2,   Mcl-1↓, 2,   MDM2↓, 2,   MOMP↓, 1,   p27↓, 1,   p27↑, 1,   p38↑, 2,   survivin↓, 11,   TNFR 1↑, 1,   TRAILR↑, 1,  

Kinase & Signal Transduction ⓘ

p‑HER2/EBBR2↓, 1,   SOX9?, 1,   Sp1/3/4↓, 45,  

Transcription & Epigenetics ⓘ

cJun↓, 1,   EZH2↓, 1,   miR-21↓, 2,   miR-27a-3p↓, 2,   other↓, 2,   tumCV↓, 4,  

Protein Folding & ER Stress ⓘ

CHOP↑, 4,   p‑eIF2α↑, 2,   ER Stress↑, 5,   GRP78/BiP?, 1,   GRP78/BiP↑, 2,   HSF1↓, 1,   HSP27↓, 2,   HSP27↑, 1,   HSP90↓, 2,   PERK↑, 3,   XBP-1↑, 1,  

Autophagy & Lysosomes ⓘ

LC3II↓, 1,   SESN2↑, 1,   TumAuto↑, 4,  

DNA Damage & Repair ⓘ

DFF45↑, 1,   DNAdam↑, 5,   DNMT1↓, 2,   DNMTs↓, 1,   m-FAM72A↓, 1,   p16↑, 1,   P53?, 1,   P53↑, 4,   PARP↑, 2,   cl‑PARP↑, 3,   PCNA↓, 1,   TP53↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↓, 1,   CDK2↓, 2,   CDK4↓, 3,   Cyc↓, 1,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 8,   P21↓, 1,   P21↑, 2,   RB1↓, 1,   p‑RB1↓, 2,   TumCCA↑, 12,  

Proliferation, Differentiation & Cell State ⓘ

ALDH↓, 1,   CD24↓, 1,   cFos↓, 1,   cMET↓, 3,   cMYB↓, 1,   CSCs↓, 5,   EMT↓, 10,   ERK↓, 3,   p‑ERK↓, 1,   FOXO↓, 1,   FOXO3↑, 1,   p‑FOXO3↓, 1,   Gli1↓, 2,   GSK‐3β↓, 2,   HDAC↓, 1,   HDAC4↓, 1,   IGF-1R↓, 2,   IGFR↓, 1,   mTOR↓, 4,   Nanog↓, 2,   NOTCH1↓, 2,   NOTCH1↝, 1,   OCT4↓, 2,   P90RSK↓, 1,   PI3K↓, 2,   PTCH1↓, 1,   PTEN↑, 2,   RAS↓, 1,   SOX2↓, 2,   STAT1↓, 2,   STAT3↓, 11,   p‑STAT3↓, 1,   STAT6↓, 1,   TOP1↓, 6,   TOP2↓, 2,   TumCG↓, 7,   Wnt↓, 1,   Wnt/(β-catenin)↓, 1,  

Migration ⓘ

annexin II↓, 1,   AP-1↓, 3,   AP-1↝, 1,   Ca+2↑, 3,   Ca+2↝, 1,   COL1↓, 1,   COL3A1↓, 1,   CXCL12↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 3,   FAK↓, 2,   GLI2↓, 1,   Ki-67↓, 1,   LAMs↓, 2,   LEF1↓, 1,   MALAT1↓, 1,   MMP2↓, 8,   MMP7↓, 1,   MMP9↓, 9,   MMPs↓, 3,   N-cadherin↓, 2,   PDGF↓, 1,   RAGE↓, 1,   Rho↓, 1,   ROCK1↓, 1,   Slug↓, 2,   Smad1↑, 1,   Snail↓, 2,   SOX4↑, 1,   TGF-β↓, 2,   TIMP1↑, 1,   TIMP2↑, 2,   TSP-1↑, 1,   TumCI↓, 13,   TumCMig↓, 8,   TumCP↓, 10,   TumMeta↓, 7,   Twist↓, 2,   uPA↓, 2,   uPAR↓, 1,   Vim↓, 4,   α-SMA↓, 1,   β-catenin/ZEB1↓, 6,  

Angiogenesis & Vasculature ⓘ

angioG↓, 12,   ATF4↑, 1,   ATF4↝, 1,   EGFR↓, 8,   Hif1a↓, 5,   Hif1a↑, 1,   Hif1a↝, 1,   NO↑, 1,   PDGFR-BB↑, 1,   VEGF↓, 16,   VEGFR2↓, 1,   ZBTB10↑, 2,  

Barriers & Transport ⓘ

BBB↑, 1,   P-gp↓, 4,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 4,   CXCR4↓, 2,   ICAM-1↓, 2,   IFN-γ↓, 1,   IKKα↓, 2,   IL1β↓, 1,   IL6↓, 5,   IL8↓, 2,   Inflam↓, 4,   JAK1↓, 2,   JAK2↓, 3,   MCP1↓, 1,   NF-kB↓, 19,   NF-kB↑, 1,   p‑NF-kB↓, 1,   p50↓, 1,   p65↓, 3,   PGE2↓, 2,   PSA↓, 1,   TNF-α↓, 2,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 2,   CDK6↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 5,   BioAv↑, 7,   BioEnh↑, 1,   ChemoSen↑, 16,   Dose↝, 1,   eff↓, 2,   eff↑, 14,   Half-Life↝, 1,   MDR1↓, 1,   MRP1↓, 1,   P450↓, 1,   RadioS↑, 6,   selectivity↑, 9,  

Clinical Biomarkers ⓘ

AR↓, 2,   EGFR↓, 8,   EZH2↓, 1,   p‑HER2/EBBR2↓, 1,   hTERT/TERT↓, 1,   IL6↓, 5,   Ki-67↓, 1,   PSA↓, 1,   RAGE↓, 1,   TP53↑, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   chemoP↑, 1,   chemoPv↑, 4,   Risk↓, 1,   toxicity↓, 2,   toxicity↝, 1,   TumW↓, 1,  
Total Targets: 286

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 4,   Catalase↑, 2,   GPx↑, 1,   GSH↑, 3,   GSTs↑, 1,   lipid-P↓, 2,   MDA↓, 1,   NRF2↑, 3,   ROS↓, 5,   SOD↑, 2,  

Core Metabolism/Glycolysis ⓘ

FASN↓, 1,   SREBP1↓, 1,  

Cell Death ⓘ

Apoptosis↓, 1,   Cyt‑c↓, 1,   IAP1↓, 1,  

Kinase & Signal Transduction ⓘ

Sp1/3/4↓, 6,  

Protein Folding & ER Stress ⓘ

HSP27↓, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↑, 1,   p62↓, 1,  

Migration ⓘ

miR-22↑, 1,   miR-29b↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   NO↑, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   Inflam↓, 4,   NF-kB↓, 1,   TLR2↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,  

Clinical Biomarkers ⓘ

ascitic↓, 1,  

Functional Outcomes ⓘ

cognitive↑, 2,   hepatoP↑, 2,   memory↑, 1,   motorD↑, 1,   neuroP↑, 1,   OS↑, 1,   toxicity↓, 2,  
Total Targets: 37

Scientific Paper Hit Count for: Sp1/3/4, Specificity Protein
13 Betulinic acid
11 Resveratrol
8 Curcumin
4 Piperlongumine
3 Ashwagandha(Withaferin A)
3 EGCG (Epigallocatechin Gallate)
2 Chemotherapy
2 Quercetin
2 Thymoquinone
1 Berberine
1 Celecoxib
1 Celastrol
1 gefitinib, erlotinib
1 Genistein (soy isoflavone)
1 Lycopene
1 Phenethyl isothiocyanate
1 Sulforaphane (mainly Broccoli)
1 Ursolic acid
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:506  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page